ArticleBrain pathology (Zurich, Switzerland)2015
Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma.
Article in Brain pathology (Zurich, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539.Neuro-oncology · 2023Trial
- Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.Journal of neurosurgery · 2018Trial
- Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539.Neuro-oncology · 2016Trial
- Factors associated with recurrence and morbidity for surgically treated WHO grade I parasagittal meningiomas.Neurosurgical review · 2026Article
- Somatostatin receptor PET in meningioma: diagnosis, therapy, and surveillance.Nuclear medicine communications · 2026Review
- Non-invasive Prediction of Meningioma Tumor Grade by Quantification of Shape-based Radiomics Features and Surface Regularity.Clinical neuroradiology · 2026Article
- Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy.British journal of cancer · 2026Article
- Review
- Novel predictors of tumor growth by exploratory quantitative analysis of radiomics features from MRI data for incidentally discovered meningioma.Journal of neuro-oncology · 2025Article
- Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67.Acta neurochirurgica · 2025Article
- Sequential omics analysis reveals molecular signatures of malignant transformation in recurrent meningiomas.Acta neuropathologica communications · 2025Article
- Optimization of Mitotic Index Quantification Using the Amnis ImageStream Imaging Flow Cytometer.Bulletin of experimental biology and medicine · 2025Article
- An evidence-based framework for postoperative surveillance of meningioma.Neuro-oncology practice · 2025Article
- Malignant Transformation of Meningiomas.Journal of Cancer · 2025Review
- The 1000 Mitoses Project: A Consensus-Based International Collaborative Study on Mitotic Figures Classification.International journal of surgical pathology · 2024Article
- Single versus multiple reoperations for recurrent intracranial meningiomas.Journal of neuro-oncology · 2024Article
- Topographic Patterns of Intracranial Meningioma Recurrences-Systematic Review with Clinical Implication.Cancers · 2024Review
- Single-cell transcriptome analysis upon ECM-remodeling meningioma cells.Neurosurgical review · 2024Article
- Meningioma Prognostic Tool Based on Correlation of Histopathological Grading and Immunohistochemistry.Oman medical journal · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
While World Health Organization (WHO) grading of meningioma stratifies patients according to recurrence risk overall, there is substantial within-grade heterogeneity with respect to recurrence-free survival (RFS). Most meningiomas are graded according to mitotic counts per unit area on hematoxylin and eosin sections, a method potentially confounded by tumor cellularity, as well as potential limitations of accurate mitotic figure detection on routine histology. To refine mitotic figure assessment, we evaluated 363 meningiomas with phospho-histone H3 (Ser10) and determined the mitotic index (number of mitoses per 1000 tumor cells). The median mitotic indices among WHO grade I (n = 268), grade II (n = 84) and grade III (n = 11) tumors were 1, 4 and 12. Classification and regression tree analysis to categorize cut-offs identified three subgroups defined by mitotic indices of 0-2, 3-4 and ≥5, which on univariate analysis were associated with RFS (P < 0.01). In multivariate analysis, mitotic index subgrouped in this manner was significantly associated with RFS (P < 0.01) after adjustment for Simpson grade, WHO grade and MIB-1 index. Mitotic index was then examined within individual WHO grade, showing that for grade I and grade II meningiomas, mitotic index can add additional information to RFS risk. The results suggest that the use of a robust mitotic marker in meningioma could refine risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.